Skip to main content

Table 2 Most commonly used adjuvants in therapeutic cancer trials

From: A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial

Number of studies including most commonly used adjuvants/immunostimulants
Adjuvant Phase 2 Phase 2/3 Phase 3 Total
GM-CSF 92 1 16 109
Montanide 60 1 5 66
IL-2 53   3 56
KLH 16   8 24
TRICOM 10   3 13
QS21 5   1 6
Poly-ICLC 8 0 0 8